|Product Candidate / Program||Drug substance||Indication||Discovery||Pre-clinical||Phase I||Phase II||Phase III / Pivotal||EMA/FDA REVIEW|
|eryaspase||Asparaginase||Pancreatic Cancer||EU then EU/US|
Pancreatic cancer is a particularly aggressive cancer, with a five-year survival rate of less than 10%. We believe pancreatic cancer is a suitable indication for eryaspase because it involves a large proportion of tumors that are believed to be sensitive to L-asparaginase depletion, allowing our product candidate to potentially have an impact.
A phase 2b study showed positive results on 140 patients suffering from metastatic pancreatic cancer in second line.